Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matritech seeks expanded approval for cancer test:

This article was originally published in Clinica

Executive Summary

Matritech is seeking to expand US approval for its NMP22 bladder cancer test to include initial detection of the disease. The test is currently approved by the FDA for the management of patients already diagnosed with bladder cancer, although the Japanese government has authorised reimbursement for its use in cancer screening. The Newton, Massachusetts-based company has submitted results of a clinical study involving 1,147 subjects to the FDA, which found that the test had 85% sensitivity in detecting late stage bladder cancer, in high-risk but previously undiagnosed patients. Overall sensitivity to all forms of bladder cancer was 70%.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079071

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel